AARDEX Group is dedicated to advancing clinical research and improving patient outcomes through our innovative solutions for measuring and managing medication adherence. We recognize that clinical trials are complex endeavors requiring multiple stakeholders' involvement, each with unique expertise and capabilities. That's why we have built an ecosystem of partners who share our vision and commitment to improving patient outcomes through clinical trial success.
Our ecosystem includes some of the most prominent and respected names in the industry, including CMOs, CROs, EDC, IRT, DCT vendors, and several industry-leading adherence packaging and device developers. By collaborating with these partners, AARDEX Group is leading the way in streamlining the approach to measuring and managing adherence in various clinical trial settings, including site-based, hybrid, and decentralized.
Our partners bring a wealth of knowledge and expertise to the table. By working together, we can develop innovative solutions that address the unique challenges of clinical trial adherence management. Our collective efforts are transforming how medication adherence is measured and managed, resulting in more accurate data and improved patient outcomes.
At AARDEX Group, we are proud to be part of a network of partners that is making a significant impact on the field of clinical research. Our commitment to advancing clinical trial success through collaboration and innovation is unwavering, and we look forward to continuing to work with our partners to improve the lives of patients everywhere.
WEBINAR WITH MERCK & BIOGEN
Mitigating the Risk of Poor Adherence in Trials
Watch this live recording with adherence experts from Merck & Biogen to learn about their approach to mitigating the risk of poor adherence in trials.
FROM THE AARDEX GROUP BLOG
We are thrilled to feature expert insights from Bernard Vrijens, a world-renowned expert on medication adherence. Taking medication as prescribed is crucial to achieving optimal health outcomes, yet non-adherence is a prevalent issue. Bernard Vrijens' extensive research and experience in the field provide invaluable insights into the factors that contribute to medication non-adherence and effective strategies to address them. His contributions to our medication adherence blog offer actionable advice and evidence-based recommendations to improve medication adherence and ultimately, patient outcomes.
In 1920, The Lancet published a paper authored by T.C. Graves entitled ‘Commentary on a case of hystero-epilepsy with delayed puberty: Treated with testicular extract’. While the article was not the first to mention the placebo effect, it is recognised
In observance of Rare Disease Day, it is imperative to underscore the progressive strides within the domain of rare disease research. Rare diseases, characterized by their infrequent occurrence within the general populace, impose significant burdens not only on the affected
It is human nature for people to trust the things that are known to them ahead of the things that are not. Familiarity, after all, brings with it a sense of comfort and reassurance. It is perhaps understandable, therefore, that
In this article, AARDEX Group Quality Manager, Oana Paun, discusses ALCOA+ and its importance for achieving regulatory compliance. For those with a scientific ear, it can be reassuring when you hear ideas discussed in terms of data. The word alone
The list of Neurological conditions is considerable, with epilepsy, Alzheimer’s disease, dementia, stroke, migraine, multiple sclerosis, Parkinson’s disease, neuro infections, and brain tumors, all attributed to this category of disease. Hundreds of millions of people worldwide are affected by neurological
It’s an uncomfortable truth that decision-making is a murky business. While we would all like to think that our actions and the choices underpinning them are rooted in logic, integrity, and reason, the truth is not entirely clear-cut. In reality,